|
1
|
Thompson LD: Osteosarcoma. Ear Nose Throat
J. 92:288–290. 2013.PubMed/NCBI
|
|
2
|
Yang J and Zhang W: New molecular insights
into osteosarcoma targeted therapy. Curr Opin Oncol. 25:398–406.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fortuna-Costa A, Gomes AM, Kozlowski EO,
Stelling MP and Pavão MS: Extracellular galectin-3 in tumor
progression and metastasis. Front Oncol. 4:1382014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Viguier M, Advedissian T, Delacour D,
Poirier F and Deshayes F: Galectins in epithelial functions. Tissue
Barriers. 2:e291032014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Laderach DJ, Gentilini L, Jaworski FM and
Compagno D: Galectins as new prognostic markers and potential
therapeutic targets for advanced prostate cancers. Prostate Cancer.
2013:5194362013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eisa NH, Ebrahim MA, Ragab M, Eissa LA and
El-Gayar AM: Galectin-3 and matrix metalloproteinase-9: Perspective
in management of hepatocellular carcinoma. J Oncol Pharm Pract.
2014.Epub ahead of print. PubMed/NCBI
|
|
7
|
von Klot CA, Kramer MW, Peters I,
Hennenlotter J, Abbas M, Scherer R, Herrmann TR, Stenzl A, Kuczyk
MA, Serth J and Merseburger AS: Galectin-1 and Galectin-3 mRNA
expression in renal cell carcinoma. BMC Clin Pathol. 14:152014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou X, Jing J, Peng J, Mao W, Zheng Y,
Wang D, Wang X, Liu Z and Zhang X: Expression and clinical
significance of galectin-3 in osteosarcoma. Gene. 546:403–407.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hou F, Wang L, Wang H, Gu J, Li M, Zhang
J, Ling X, Gao X and Luo C: Elevated gene expression of S100A12 is
correlated with the predominant clinical inflammatory factors in
patients with bacterial pneumonia. Mol Med Rep. 11:4345–4352.
2015.PubMed/NCBI
|
|
10
|
Gao J, Ding F, Liu Q and Yao Y: Knockdown
of MACC1 expression suppressed hepatocellular carcinoma cell
migration and invasion and inhibited expression of MMP2 and MMP9.
Mol Cell Biochem. 376:21–32. 2013. View Article : Google Scholar
|
|
11
|
Miao JH, Wang SQ, Zhang MH, Yu FB, Zhang
L, Yu ZX and Kuang Y: Knockdown of galectin-1 suppresses the growth
and invasion of osteosarcoma cells through inhibition of the
MAPK/ERK pathway. Oncol Rep. 32:1497–1504. 2014.PubMed/NCBI
|
|
12
|
Tsubaki M, Satou T, Itoh T, Imano M, Ogaki
M, Yanae M and Nishida S: Reduction of metastasis, cell invasion
and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced
blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway. Toxicol Appl
Pharmacol. 259:402–410. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Diao CY, Guo HB, Ouyang YR, Zhang HC, Liu
LH, Bu J, Wang ZH and Xiao T: Screening for metastatic osteosarcoma
biomarkers with a DNA microarray. Asian Pac J Cancer Prev.
15:1817–1822. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao P, Simpson JL, Zhang J and Gibson PG:
Galectin-3: Its role in asthma and potential as an
anti-inflammatory target. Respir Res. 14:1362013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sundblad V, Croci DO and Rabinovich GA:
Regulated expression of galectin-3, a multifunctional
glycan-binding protein, in haematopoietic and non-haematopoietic
tissues. Histol Histopathol. 26:247–265. 2011.
|
|
16
|
Funasaka T, Raz A and Nangia-Makker P:
Galectin-3 in angio-genesis and metastasis. Glycobiology.
24:886–891. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Leal MF, Calcagno DQ, Chung J, de Freitas
VM, Demachki S, Assumpção PP, Chammas R, Burbano RR and Smith MC:
Deregulated expression of annexin-A2 and galectin-3 is associated
with metastasis in gastric cancer patients. Clin Exp Med. 2014.Epub
ahead of print.
|
|
18
|
Truran PP, Johnson SJ, Bliss RD, Lennard
TW and Aspinall SR: Parafibromin, galectin-3, PGP9.5, Ki67 and
cyclin D1: Using an immunohistochemical panel to aid in the
diagnosis of parathyroid cancer. World J Surg. 38:2845–2854. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mirandola L, Nguyen DD, Rahman RL, Grizzi
F, Yuefei Y, Figueroa JA, Jenkins MR, Cobos E and Chiriva-Internati
M: Anti-Galectin-3 therapy: A new chance for multiple myeloma and
ovarian cancer? Int Rev Immunol. 33:417–427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
van den Brûle F, Califice S and Castronovo
V: Expression of galectins in cancer: A critical review. Glycoconj
J. 19:537–542. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng D, Hu Z, He F, Gao C, Xu L, Zou H,
Wu Z, Jiang X and Wang J: Downregulation of galectin-3 causes a
decrease in uPAR levels and inhibits the proliferation, migration
and invasion of hepatocellular carcinoma cells. Oncol Rep.
32:411–418. 2014.PubMed/NCBI
|
|
22
|
Huang CX, Zhao JN, Zou WH, Li JJ, Wang PC,
Liu CH and Wang YB: Reduction of galectin-3 expression reduces
pituitary tumor cell progression. Genet Mol Res. 13:6892–6898.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Y, Balan V, Kho D, Hogan V,
Nangia-Makker P and Raz A: Galectin-3 regulates p21 stability in
human prostate cancer cells. Oncogene. 32:5058–5065. 2013.
View Article : Google Scholar
|
|
24
|
Kosacka M, Piesiak P, Kowal A, Golecki M
and Jankowska R: Galectin-3 and cyclin D1 expression in non-small
cell lung cancer. J Exp Clin Cancer Res. 30:1012011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang D, Chen ZG, Liu SH, Dong ZQ, Dalin
M, Bao SS, Hu YW and Wei FC: Galectin-3 gene silencing inhibits
migration and invasion of human tongue cancer cells in vitro via
downregulating β-catenin. Acta Pharmacol Sin. 34:176–184. 2013.
View Article : Google Scholar
|
|
26
|
Song S, Ji B, Ramachandran V, Wang H,
Hafley M, Logsdon C and Bresalier RS: Overexpressed galectin-3 in
pancreatic cancer induces cell proliferation and invasion by
binding Ras and activating Ras signaling. PLoS One. 7:e426992012.
View Article : Google Scholar : PubMed/NCBI
|
